Drug Profile


Alternative Names: LC 33; YM 09222

Latest Information Update: 05 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ajinomoto
  • Developer Ajinomoto; EA Pharma; Taiho Pharmaceutical
  • Class Antineoplastics; Antivirals; Beta Glucans
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • No development reported Breast cancer; Colorectal cancer; HIV infections; Liver cancer; Lung cancer; Prostate cancer

Most Recent Events

  • 21 Jun 2017 EA Pharma decides to withdraw lentinan (IV, Injection) for the treatment of Gastric Cancer in Japan as the demand for the product has dropped
  • 30 Nov 2005 No development reported - Clinical-Phase-Unknown for Breast cancer in Japan (unspecified route)
  • 30 Nov 2005 No development reported - Clinical-Phase-Unknown for Colorectal cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top